In Vitro and In Vivo Analyses of Constitutive and In Vivo-Induced Promoters in Attenuated Vaccine and Vector Strains of Vibrio cholerae
Open Access
- 1 March 2000
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 68 (3) , 1171-1175
- https://doi.org/10.1128/iai.68.3.1171-1175.2000
Abstract
The optimal promoter for in vivo expression of heterologous antigens by live, attenuated vaccine vector strains of Vibrio cholerae is unclear; in vitro analyses of promoter activity may not accurately predict expression of antigens in vivo. We therefore introduced plasmids expressing the B subunit of cholera toxin (CtxB) under the control of a number of promoters into V. cholerae vaccine strain Peru2. We evaluated the tac promoter, which is constitutively expressed in V. cholerae , as well as the in vivo-induced V. cholerae heat shock htpG promoter and the in vivo-induced V. cholerae iron-regulated irgA promoter. The functionality of all promoters was confirmed in vitro. In vitro antigenic expression was highest in vaccine strains expressing CtxB under the control of the tac promoter (2 to 5 μg/ml/unit of optical density at 600 nm [OD 600 ]) and, under low-iron conditions, in strains containing the irgA promoter (5 μg/ml/OD 600 ). We orally inoculated mice with the various vaccine strains and used anti-CtxB immune responses as a marker for in vivo expression of CtxB. The vaccine strain expressing CtxB under the control of the tac promoter elicited the most prominent specific anti-CtxB responses in vivo (serum immunoglobulin G [IgG], P ≤ 0.05; serum IgA, P ≤ 0.05; stool IgA, P ≤ 0.05; bile IgA, P ≤ 0.05), despite the finding that the tac and irgA promoters expressed equivalent amounts of CtxB in vitro. Vibriocidal antibody titers were equivalent in all groups of animals. Our results indicate that in vitro assessment of antigen expression by vaccine and vector strains of V. cholerae may correlate poorly with immune responses in vivo and that of the promoters examined, the tac promoter may be best suited for expression from plasmids of at least certain heterologous antigens in such strains.Keywords
This publication has 16 references indexed in Scilit:
- Optimizing the Germfree Mouse Model for In Vivo Evaluation of Oral Vibrio cholerae Vaccine and Vector StrainsInfection and Immunity, 2000
- Development of a Δ glnA Balanced Lethal Plasmid System for Expression of Heterologous Antigens by Attenuated Vaccine Vector Strains of Vibrio choleraeInfection and Immunity, 2000
- Development Of A Live, Oral, Attenuated Vaccine Against El Tor CholeraThe Journal of Infectious Diseases, 1994
- Emergence of a New Cholera Pandemic: Molecular Analysis of Virulence Determinants in Vibrio cholerae 0139 and Development of a Live Vaccine PrototypeThe Journal of Infectious Diseases, 1994
- Use of the Vibrio cholerae irgA gene as a locus for insertion and expression of heterologous antigens in cholera vaccine strainsVaccine, 1993
- Use of the nirB Promoter to Direct the Stable Expression of Heterologous Antigens in Salmonella Oral Vaccine Strains: Development of a Single–Dose Oral Tetanus VaccineNature Biotechnology, 1992
- Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory.Journal of Clinical Investigation, 1991
- SAFETY, IMMUNOGENICITY, AND EFFICACY OF RECOMBINANT LIVE ORAL CHOLERA VACCINES, CVD 103 AND CVD 103-HgRThe Lancet, 1988
- Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine developmentNature, 1983
- Duration of Infection-Derived Immunity to CholeraThe Journal of Infectious Diseases, 1981